B1AX34 Stock Overview Through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Baxter International Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Baxter International Historical stock prices Current Share Price US$95.15 52 Week High US$110.00 52 Week Low US$86.51 Beta 0.61 1 Month Change 3.45% 3 Month Change -2.21% 1 Year Change -9.77% 3 Year Change -57.23% 5 Year Change -48.32% Change since IPO -50.13%
Recent News & Updates
Baxter International Inc. Reports Unaudited Consolidated Impairments for the Fourth Quarter Ended December 31, 2024 Feb 21
Baxter International Inc. Announces Chief Executive Officer Changes Feb 04 Baxter International Inc. to Report Q4, 2024 Results on Feb 20, 2025
Baxter International Inc. Announces Executive Changes Feb 01
Baxter International Inc. Announces Continued Growth of Pharmaceuticals Portfolio with Five Injectable Product Launches in the U.S Dec 11
Baxter International Inc. Announces Resignation of Peter M. Wilver as Board of Directors, and the Audit Committee and Compensation and Human Capital Committee, Effective December 31, 2024 Nov 23 See more updates
Baxter International Inc. Reports Unaudited Consolidated Impairments for the Fourth Quarter Ended December 31, 2024 Feb 21
Baxter International Inc. Announces Chief Executive Officer Changes Feb 04 Baxter International Inc. to Report Q4, 2024 Results on Feb 20, 2025
Baxter International Inc. Announces Executive Changes Feb 01
Baxter International Inc. Announces Continued Growth of Pharmaceuticals Portfolio with Five Injectable Product Launches in the U.S Dec 11
Baxter International Inc. Announces Resignation of Peter M. Wilver as Board of Directors, and the Audit Committee and Compensation and Human Capital Committee, Effective December 31, 2024 Nov 23
Baxter International Inc. Declares Quarterly Dividend, Payable on January 2, 2025 Nov 13
Baxter International Inc. Declares Quarterly Dividend, Payable on January 2, 2025 Nov 12
Baxter International Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2024 Nov 08 Baxter International Inc. Provides Update on North Cove, N.C., Facility Oct 01
-Baxter International Inc. Appoints Jeffrey A. Craig to Its Board Sep 11 The Carlyle Group Inc. (NasdaqGS:CG) and Atmas Health entered into an Equity Purchase Agreement to acquire Vantive Health LLC from Baxter International Inc. (NYSE:BAX) for $3.8 billion. Aug 14
Baxter International Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2024 Aug 07
Baxter International Inc. Announces Launch of the Helion Integrated Surgical System in Thailand Jul 30
Baxter International Inc. Declares Quarterly Dividend, Payable on October 1, 2024 Jul 17
Carlyle Group Reportedly in Advanced Talks to Buy Baxter's Vantive Business Jul 06
Baxter International Inc. Announces New Data Showing Expanded Hemodialysis, Known as HDX Therapy May 30
Baxter International Inc. Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication May 14
Baxter International Inc. Declares Quarterly Dividend, Payable on July 1, 2024 May 08
Baxter International Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2024 May 03
Baxter International Inc. Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S Apr 11
Baxter International Inc. Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy Apr 03
Baxter International Inc., Annual General Meeting, May 07, 2024 Mar 26
Baxter International Inc. Declares Quarterly Dividend, Payable on April 1, 2024 Feb 13
Baxter International Inc. Provides Sales Guidance for the First Quarter and Full Year 2024 Feb 08
Baxter International Inc. Announces the Completion of the First Phase of Its Intravenous (IV) Bag Recycling Program Pilot Dec 14
Baxter International Inc. Declares Quarterly Dividend, Payable on January 2, 2024 Nov 15
Baxter International Inc. Highlights New Data At Kidney Week Indicating Sharesource Is Associated with A 77% Lower Risk of Home Dialysis Technique Failure Nov 07 Baxter International Inc. Provides Earnings Guidance for the Fourth Quarter and Year 2023
Baxter International Inc. Digital Image Capture Capability for PanOptic Plus Ophthalmoscope Oct 17 Baxter International Inc. Announces Management Appointments
Levi & Korsinsky Notifies Baxter International Inc. Investors of A Class Action Lawsuit and Upcoming Deadline Sep 06
Baxter International Inc. Announces Board Changes Aug 22
The Klein Law Firm Announces That A Class Action Complaint Has Been Filed on Behalf of Shareholders of Baxter International Inc. Alleging That the Company Violated Federal Securities Laws Aug 02
Baxter International Inc. Launches PERCLOT Absorbable Hemostatic Powder Jul 25
Baxter International Inc. Declares Quarterly Cash Dividend, Payable on October 2, 2023 Jul 21
Rosen Law Firm Announces the Filing of Class Action Lawsuit on Behalf of Purchasers of Securities of Baxter International Inc Jul 14 Baxter International Inc. Appoints William Ampofo to Its Board of Directors Baxter International Inc.(NYSE:BAX) dropped from Russell 1000 Growth Index Baxter International Inc. Announces James K. Saccaro Notifies to Resign as Executive Vice President, Effective as of May 31, 2023 Advent International Corporation and Warburg Pincus LLC signed a definitive agreement to acquire Baxter Pharmaceutical Solutions LLC from Baxter International Inc. (NYSE:BAX) for $4.3 billion.
Baxter International Inc. Selects Chris Toth to Be Chief Executive Officer of the Company’s Planned Spinoff of Its Renal Care and Acute Therapies Businesses May 06
Baxter International Inc. Announces Management Changes Feb 16
Baxter International Inc. Declares Quarterly Dividend, Payable on April 3, 2023 Feb 15 Baxter International Inc. Reports Goodwill Impairment for the Fourth Quarter Ended December 31, 2022
Baxter International Inc. Announces Resignation of Giuseppe Accogli as Executive Vice President and Chief Operating Officer Jan 07
Baxter Introduces ExactaMix Pro Automated Compounder Dec 02
Baxter International Inc. Declares Quarterly Cash Dividend, Payable on January 3, 2023 Nov 16 Baxter International Inc. Highlights New Home Dialysis and HDX Therapy Data in 14 Clinical Presentations At Kidney Week 2022 Nov 08
Baxter International Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022 Oct 28 Baxter International Inc. to Report Q3, 2022 Results on Oct 27, 2022 Sep 08
Baxter International Inc. Announces U.S. FDA Clearance of Novum IQ Syringe Infusion Pump with Dose IQ Safety Software Sep 01
Baxter International Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2022 Jul 29
Baxter International Inc. Announces Executive Changes Jul 21
Baxter International Inc. Declares Quarterly Dividend, Payable on October 3, 2022 Jul 13
Baxter International Inc. Announces Board Changes May 09
Baxter International Inc. Declares Quarterly Dividend, Payable on July 1, 2022 May 04
Baxter International Inc. Announces Findings of an Observational Study on Data from the Starling Registry Apr 20
Baxter Announces U.S. FDA Clearance of ST Set Used to Help Treat Acute Kidney Injury Patients in the Hospital Apr 06
Baxter International Inc., Annual General Meeting, May 03, 2022 Mar 23
Baxter International Inc. Presents Data Indicating Sharesource Increases Patients’ Time on Home Dialysis by More Than Three Months Mar 03
Baxter International Inc. Provides Earnings Guidance for the First Quarter and Year of 2022 Feb 18
Baxter International Inc. Declares Quarterly Cash Dividend, Payable on April 1, 2022 Feb 15
Baxter International Inc. Announces U.S. FDA Approval and Launch of Ready-to-use Cardiovascular Medicine Norepinephrine in Premix Formulation Sep 24
Baxter Reportedly in Advanced Talks to Acquire Hill-Rom for About $10 Billion Aug 30 Baxter International Inc.(NYSE:BAX) dropped from Russell 1000 Growth-Defensive Index
Baxter International Inc. Presents Data At 58th ERA-EDTA Congress Indicating Theranova May Reduce Cardiovascular Events and Hospitalizations Jun 09
Baxter Launches the Sharesource Analytics 1.0 Digital Health Module to Enhance Clinical Management of Home Dialysis Patients Jun 03
Bernstein Litowitz Berger & Grossmann LLP and Kessler Topaz Meltzer & Check, LLP Announce Settlement of Class Action Involving Purchasers of Baxter International Inc. Common Stock Jun 02
Baxter International Inc. Launches PrisMax2 System to Advance Critical Care Delivery for Patients and Hospitals May 26
Baxter International Inc. Declares Quarterly Cash Dividend, Payable on July 1, 2021 May 04
Baxter International Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2021 Apr 30
Baxter Announces U.S. FDA 510(K) Clearance of AK 98 Hemodialysis Machine Mar 14
Baxter International Inc. Announces Board Changes Feb 18 Shareholder Returns B1AX34 BR Medical Equipment BR Market 7D 10.0% -0.7% -1.3% 1Y -9.8% 8.1% -7.8%
See full shareholder returns
Return vs Market: B1AX34 underperformed the BR Market which returned -8.2% over the past year.
Price Volatility Is B1AX34's price volatile compared to industry and market? B1AX34 volatility B1AX34 Average Weekly Movement n/a Medical Equipment Industry Average Movement 6.1% Market Average Movement 5.4% 10% most volatile stocks in BR Market 9.8% 10% least volatile stocks in BR Market 3.2%
Stable Share Price: B1AX34's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: Insufficient data to determine B1AX34's volatility change over the past year.
About the Company Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.
Show more Baxter International Inc. Fundamentals Summary How do Baxter International's earnings and revenue compare to its market cap? B1AX34 fundamental statistics Market cap R$97.29b Earnings (TTM ) -R$1.92b Revenue (TTM ) R$60.61b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) B1AX34 income statement (TTM ) Revenue US$10.64b Cost of Revenue US$6.43b Gross Profit US$4.21b Other Expenses US$4.55b Earnings -US$337.00m
Last Reported Earnings
Dec 31, 2024
Earnings per share (EPS) -0.66 Gross Margin 39.58% Net Profit Margin -3.17% Debt/Equity Ratio 166.1%
How did B1AX34 perform over the long term?
See historical performance and comparison Dividends
2.0% Current Dividend Yield When do you need to buy B1AX34 by to receive an upcoming dividend? Baxter International dividend dates Ex Dividend Date Feb 27 2025 Dividend Pay Date Apr 07 2025 Days until Ex dividend 4 days Days until Dividend pay date 43 days
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/22 14:50 End of Day Share Price 2025/02/20 00:00 Earnings 2024/12/31 Annual Earnings 2024/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Baxter International Inc. is covered by 44 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jasper Hellweg Argus Research Company Benjamin Yeoh Atlantic Equities LLP Daniel Owczarski Avondale Partners
Show 41 more analysts 
